Purified Protein Derivative of Bovine Tuberculin (PPD-B) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a diagnostic antigen intermediate prepared from heat-sterilized culture filtrates of Mycobacterium bovis strain AN5. The principal compendially recognized use is the manufacture of intradermal test solutions for detection of bovine tuberculosis, including the single cervical test and the comparative cervical test with avian tuberculin PPD-A. The commercial product title lists multiple physical presentation suffixes, but the licensed immunodiagnostic application remains the sterile intradermal injection. Powder, granule, tablet, capsule, and premix presentations are not established as orally active tuberculin dosage forms in Ph. Eur. 0535, USDA 9 CFR 113.409, or the OIE Terrestrial Manual Chapter 3.4.6; published data for these specific configurations is limited. Where such non-injection forms are listed in a supply chain, they are considered bulk handling forms or manufacturer-specific intermediates rather than validated final diagnostic products.

Why Is Potency Expressed as International Units Rather Than Total Protein Mass?

PPD-B active substance is a complex mixture of low-molecular-weight mycobacterial proteins and peptides, and its biological activity cannot be assigned by a simple gravimetric protein determination alone. Commercial release documentation therefore includes a potency assignment expressed in International Units per millilitre or International Units per vial. Common liquid working strengths for licensed veterinary tuberculins include 20,000 IU/mL and 25,000 IU/mL, with a standard intradermal dose of 0.1 mL in many regional protocols. For lyophilized powders, the potency is assigned after reconstitution in a manufacturer-specified diluent. The production model designation frequently contains the strain identifier AN5, the presentation form, and the assigned potency, for example a 20,000 IU/mL bulk solution or a lyophilized vial calibrated to 20,000 IU per dose unit. Potency calibration is performed against a reference preparation traceable to regional pharmacological standards; compendial acceptance limits follow the specific veterinary tuberculin monograph.

Total protein concentration is included as a release parameter but is not a substitute for potency. Typical compendial release panels for this API include appearance, identity, total protein, potency in sensitized guinea pigs, pH, sterility, bacterial endotoxins, and residual moisture where applicable. Identity may be confirmed by peptide profile or immunological reactivity against a reference antiserum. pH is measured by Ph. Eur. 2.2.3 or USP <791>. Sterility is assessed by membrane filtration according to Ph. Eur. 2.6.1 or USP <71>. Endotoxin testing follows Ph. Eur. 2.6.14 or USP <85>. Moisture in lyophilized material is determined by Karl Fischer titration according to USP <921> or corresponding regional methods. Because the API is a protein antigen, inappropriate storage, repeated freeze-thaw cycles, or prolonged exposure to temperatures above 2–8 °C may reduce potency without changing total protein content.

Production Vessel Controls and Antigen Consistency in Bulk PPD-B Manufacture

Preparation of PPD-B requires cultivation of Mycobacterium bovis strain AN5 on synthetic or semi-synthetic liquid medium under controlled aeration. Production-scale stainless-steel or single-use stirred-tank bioreactors are used, with extended incubation at 37 ± 1 °C. After sufficient antigen accumulation, the culture is heat-inactivated under conditions sufficient to kill viable mycobacteria, commonly autoclaving at 121 °C for 30 minutes. The heat-killed broth is clarified by filtration or centrifugation, and tuberculin protein is recovered by precipitation, washing, and diafiltration. Residual precipitation salts and low-molecular-weight medium components are removed using tangential-flow filtration with low-molecular-weight cut-off membranes. The resulting concentrated protein solution is formulated with buffer and preservative, sterile-filtered through 0.22 µm membranes, and filled as a liquid or lyophilized bulk product.

Batch-to-batch variation in PPD-B is a recognized production issue because the antigen is not a single purified recombinant protein but a culture filtrate fraction containing multiple mycobacterial components. Harvest time, aeration profile, medium composition, and precipitation conditions influence the relative abundance of individual antigenic fractions. Production-scale behavior therefore requires in-process monitoring of protein yield and potency rather than reliance on final total protein alone. Sensitized guinea pig potency testing is used as the biological release assay because it integrates antigenic activity across the protein mixture. Operators performing comparative cervical testing in cattle should not interchange PPD-B lots without recording lot-specific potency and validating injection volume because skin induration response is dose-dependent. Published data for specific bioreactor configuration-to-antigenic specificity relationships is limited.

Protein adsorption to glass and elastomer surfaces at low concentration can reduce deliverable potency during bulk storage and fill-finish. Lyophilized formulations with an inert bulking agent are preferred when extended storage or transport above refrigerated conditions is anticipated. Reconstituted solutions are sterile and intended for intradermal administration; they are not suitable for intravenous, intramuscular, or subcutaneous use unless explicitly authorized by a regional regulatory file. The presence of preservative in multi-dose presentations is controlled because preservative concentration above the licensed limit may interfere with intradermal response. No routine oral route for PPD-B has been established in recognized veterinary monographs.

When Comparative Cervical Testing Requires Homologous and Avian Antigens in Parallel

The comparative cervical test is used to reduce false-positive classification in herds exposed to environmental mycobacteria or paratuberculosis. In this protocol, PPD-B and PPD-A are injected at separate clipped side-by-side cervical skin sites, and skin fold thickness is measured with callipers before injection and at 72 ± 6 hours after injection. The measuring instrument should have a resolution of at least 0.1 mm, and the operator should record skin fold thickness at the same anatomical location before and after injection. The result is the change in skin thickness in millimetres for each antigen, and the interpretation is based on the difference between homologous and heterologous responses. Jurisdictional thresholds differ, but some national programs classify a PPD-B–PPD-A difference of ≥ 4 mm as positive, 1–4 mm as inconclusive, and ≤ 1 mm as negative in combination with clinical and herd-history data. These thresholds are regulatory or field-protocol values and must be confirmed against locally approved interpretation criteria.

Differences between PPD-B and PPD-A arise from the antigenic complexity of their source mycobacterial cultures. PPD-B is not a purified single antigen or a synthetic peptide; it shares epitopes with other members of the Mycobacterium tuberculosis complex and to a lesser extent with non-tuberculous mycobacteria. PPD-A provides a heterologous comparator because it contains antigens expressed by Mycobacterium avium subsp. avium and related environmental mycobacteria. In a bovine tuberculosis-infected animal, the homologous PPD-B response is usually larger than the PPD-A response. In animals sensitized by environmental mycobacteria, the PPD-A response may be equal to or greater than the PPD-B response. This comparative approach is not interchangeable with serological or interferon-gamma release assay interpretation, which uses defined antigens such as ESAT-6 and CFP-10 with different biological pathways.

Injection technique and dose delivery are critical sources of field variability. A short-bevel needle and calibrated syringe should be used, and the dose must be deposited intradermally rather than subcutaneously. A visible pea-like swelling at the injection site confirms intradermal placement. If the dose is subcutaneous or if leakage occurs, the test result may be invalid and a retest at an alternate site may be required according to local protocol. The API itself must be stored at 2–8 °C, protected from light, and used within the in-use period specified by the manufacturer after first opening. Freezing of liquid PPD-B is not recommended because protein aggregation and potency loss may occur without visible precipitation.

PPD-B Veterinary Grade API is not the same substance as human tuberculin PPD prepared from Mycobacterium tuberculosis, and it is not directly interchangeable with PPD-A or with defined mycobacterial antigen preparations used in cell-mediated immunity assays. The product is regulated as a veterinary biological or veterinary medicinal component, and batch release must comply with regional requirements for sterile manufacturing and biological potency testing. Where the supply chain lists capsules, tablets, powders, granules, or premix presentations, those designations describe potential bulk handling forms rather than a demonstrated oral diagnostic route. No recognized compendial method currently supports oral administration of PPD-B as a diagnostic antigen, and such configurations require separate stability, bioavailability, and immunological rationale before they can be considered comparable to the intradermal solution form.